Drugs / Budigalimab
Trials 25
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 118 trials · 1 met primary | ||||||
| Phase 1 | NCT07241039 | Nov 2025 → Apr 2029 expected | squamous cell carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT06158958 | Feb 2024 → Oct 2025 | cancer | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05599984 | Dec 2022 → Nov 2027 expected | cancer | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05005403 | Nov 2021 → Jul 2027 expected | colorectal cancer, gastroesophageal cancer, head and neck squamous cell carcinoma, malignant pancreatic neoplasm +3 | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT04799353 | Mar 2021 → Oct 2022 | HIV infectious disease | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT04306900 | Mar 2020 → Nov 2022 | cancer | Trishula Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04223804 | Jan 2020 → Feb 2023 | HIV infectious disease | AbbVie | Completed | Met primary |
| Phase 1 | NCT03818542 | Jan → Sep 2020 | head and neck cancer | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04196283 | Jan 2020 → Oct 2022 | cancer of unknown primary site | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT03893955 | May 2019 → Mar 2027 expected | metastatic neoplasm, non-small cell lung carcinoma, triple-negative breast carcinoma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03821935 | Feb 2019 → Jun 2027 expected | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03639194 | Oct 2018 → Jan 2024 | small cell lung carcinoma | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT03138408 | Jun 2017 → May 2019 | cancer | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03035279 | Mar 2017 → Mar 2019 | colorectal cancer | AbbVie | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02988960 | Feb 2017 → Sep 2026 overdue | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03000257 | Dec 2016 → Mar 2022 | cancer | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT02539719 | Aug 2015 → Jan 2019 | ovarian cancer | Stemcentrx | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01946074 | Aug 2013 → Sep 2022 | cancer | AbbVie | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06772623 | Mar 2025 → Nov 2027 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06632951 | Jan 2025 → Mar 2027 expected | urothelial carcinoma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06119217 | Mar 2024 → Nov 2025 | malignant pancreatic neoplasm | Trishula Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT06032546 | Oct 2023 → Sep 2025 | HIV infectious disease | AbbVie | Terminated | No outcome recorded |
| Phase 2 | NCT05822752 | Sep 2023 → Nov 2026 expected | hepatocellular carcinoma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06236438 | Apr 2024 → Oct 2031 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06109272 | Jan 2024 → Jan 2027 expected | hepatocellular carcinoma | AbbVie | Active not recruiting | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT06487559 Background | Sep 2024 → Oct 2027 expected | hepatocellular carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 1 | NCT03071757 Background | Mar 2017 → Apr 2022 | — | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT06628310 Background | Dec 2024 → Oct 2030 expected | esophageal adenocarcinoma, gastroesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | AbbVie | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-04-12 | Trishula Therapeutics, Inc. | Results Trishula Therapeutics Announces Promising Early Phase 1b Data of TTX-030, an Anti-CD39 Antibody, in Combination with Chemoimmunotherapy as First-Line Treatment for Locally Advanced or Metastatic Gastric Cancer/GEJ Cancer trishulatx.com ↗
The data presented demonstrates that TTX-030 combination treatment was generally well-tolerated and showed encouraging signs of anti-tumor activity. |
All press releases naming this drug 1 release
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 31 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | budigalimab | “budigalimab (formerly ABBV-181), an antibody targeting PD-1” PMID 32513564 ↗ Jun 2020 |
| Known as | ABBV-181 | “A Phase 1 First-in-Human, Open-Label Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABBV-711 as a Monotherapy or in Combination with Budigalimab (ABBV-181) in...” NCT07241039 ↗ |
| Known as | PR-1648817 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297858 ↗ |
| Action | Inhibit | “It is in clinical development in combination with budigalimab, an anti-programmed cell death protein 1 Fc-modified mAb.” PMID 39534099 ↗ Oct 2024 |
| Modality | Monoclonal antibody | “ABBV-181 is a humanized, recombinant, mAb that binds to cell surface expressed programmed cell death 1 (PD-1).” NCT02539719 ↗ |
| Route | Intravenous | “ABBV-181 will be administered by intravenous infusion.” NCT01946074 ↗ |
| Target | PDCD1 | “ABBV-181 is a humanized, recombinant, mAb that binds to cell surface expressed programmed cell death 1 (PD-1).” NCT02539719 ↗ |